Christopher Kim
Chairman and CMO at Apimeds Pharmaceuticals US Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 2 years
- Director since
- 2025
2 years of board service in total across 1 board, counting each seat separately. Longest: Apimeds Pharmaceuticals US Inc., 1 year.
Apimeds Pharmaceuticals US Inc.
Director · Chairman and CMO
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 16, 2025 | Apimeds Pharmaceuticals US Inc. | Grant or award | +250,000 | — | — |
| May 14, 2025 | Apimeds Pharmaceuticals US Inc. | Open-market purchase | +7,730 | $1.86 | $14,378 |
| May 13, 2025 | Apimeds Pharmaceuticals US Inc. | Open-market purchase | +19,770 | $1.82 | $35,981 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.